Moderna Stock Is Soaring. Is It Too Late to Buy?
Moderna's growth story is just beginning.
Overview
Moderna's (NASDAQ: MRNA) share price has more than doubled this year as the market has grown increasingly optimistic about the company's pipeline and encouraging regulatory progress for its flu vaccine. But after such a sharp rally, it's fair to ask whether there's still an opportunity here to make some money.
The investment case for Moderna isn't just about COVID-19 vaccines anymore. It's about what comes next.
Details
Today, the company has three commercial products, multiple late-stage vaccine programs, and an expanding pipeline that stretches well beyond infectious diseases. Moderna is developing personalized cancer vaccines in partnership with Merck and pursuing therapies for rare genetic disorders.
Source
Originally published at www.fool.com.